de Lange IM, et al. - Experts aspired to explore clinical features that can help predict the evolution of seizures into Dravet syndrome and clinical features that predict cognitive outcome in Dravet syndrome as well as investigating the role of contraindicated medication (CIM) as a possible modifier of cognitive decline. For this investigation, a cohort of one hundred sixty-four Dutch members with SCN1A-related seizures was evaluated. In Dravet syndrome, a longer CIM use in the first 5 years of a disease could have negative effects on cognitive outcome. Therefore, an early diagnosis was essential to avoid these drugs. Age at first afebrile seizure was identified as an important predictor for the evolution of seizures into Dravet syndrome and for the severity of Dravet syndrome, which could be used to counsel parents of young patients with SCN1A-related seizures.